Immune checkpoint inhibition in early-stage triple-negative breast cancer

R Varma, M Wright, J Abraham… - Expert review of …, 2022 - Taylor & Francis
Introduction Breast cancer cells can evade immune recognition by upregulating
programmed death-ligand 1 (PD-L1) leading to decreased T cell function. Anti-PD-1 agents …
被引用次数：3 相关文章

Immune checkpoint inhibition in early-stage triple-negative breast cancer

R Varma, M Wright, J Abraham… - Expert review of …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Breast cancer cells can evade immune recognition by upregulating
programmed death-ligand 1 (PD-L1) leading to decreased T cell function. Anti-PD-1 agents …

Immune checkpoint inhibition in early-stage triple-negative breast cancer.

J Abraham, R Varma, M Wright… - Expert Review of …, 2022 - europepmc.org
Breast cancer cells can evade immune recognition by upregulating programmed death-
ligand 1 (PD-L1) leading to decreased T cell function. Anti-PD-1 agents, like …

Immune checkpoint inhibition in early-stage triple-negative breast cancer

R Varma, M Wright, J Abraham… - Expert review of …, 2022 - mdanderson.elsevierpure.com
Introduction: Breast cancer cells can evade immune recognition by upregulating
programmed death-ligand 1 (PD-L1) leading to decreased T cell function. Anti-PD-1 agents …